FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel- results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO

Lorenzen, Sylvie; Thuss-Patience, Peter; Pauligk, Claudia; Goekkurt, Eray; Ettrich, Thomas; Lordick, Florian; Stahl, Michael; Reichardt, Peter; Soekler, Martin; Pink, Daniel; Probst, Stefan; Hinke, Axel; Goetze, Thorsten O.; Al-Batran, Salah E.

dc.contributor.author	Sökler, Martin
dc.date.accessioned	2023-04-24T10:12:26Z
dc.date.available	2023-04-24T10:12:26Z
dc.date.issued	2022
dc.identifier.issn	0959-8049
dc.identifier.uri	http://hdl.handle.net/10900/139535
dc.language.iso	en	de_DE
dc.publisher	Elsevier Sci Ltd	de_DE
dc.relation.uri	http://dx.doi.org/10.1016/j.ejca.2022.01.015	de_DE
dc.subject.ddc	610	de_DE
dc.title	FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel- results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO	de_DE
dc.type	Article	de_DE
utue.quellen.id	20220728000000_01385
utue.publikation.seiten	48-57	de_DE
utue.personen.roh	Lorenzen, Sylvie
utue.personen.roh	Thuss-Patience, Peter
utue.personen.roh	Pauligk, Claudia
utue.personen.roh	Goekkurt, Eray
utue.personen.roh	Ettrich, Thomas
utue.personen.roh	Lordick, Florian
utue.personen.roh	Stahl, Michael
utue.personen.roh	Reichardt, Peter
utue.personen.roh	Soekler, Martin
utue.personen.roh	Pink, Daniel
utue.personen.roh	Probst, Stefan
utue.personen.roh	Hinke, Axel
utue.personen.roh	Goetze, Thorsten O.
utue.personen.roh	Al-Batran, Salah E.
dcterms.isPartOf.ZSTitelID	European Journal of Cancer	de_DE
dcterms.isPartOf.ZS-Volume	165	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE